


**Product Name** : TBI-223  
**Cat. No.** : PC-20073  
**CAS No.** : 2071265-08-0  
**Molecular Formula** : C<sub>17</sub>H<sub>20</sub>FN<sub>3</sub>O<sub>5</sub>  
**Molecular Weight** : 365.36  
**Target** : Bacterial  
**Solubility** : 10 mM in DMSO



## Biological Activity

TBI-223 is an oxazolidinone with excellent oral bioavailability and activity against Gram-positive bacteria, works as **protein synthesis** inhibitor, targets an early step involving the binding of N-formylmethionyl-tRNA to the ribosome.

TBI-223 showed reduced human and mouse bone marrow progenitor cell toxicity in vitro and bone marrow toxicity in rat and dog models in vivo, compared to linezolid.

TBI-223 had broader efficacy against other antibiotic-resistant Gram-positive bacteria, including vancomycin-resistant enterococci, penicillin- and ceftriaxone-resistant *Streptococcus pneumoniae*, and coagulase-negative staphylococci. TBI-223 had activity in vitro and in vivo against other bacteria, such as drug-sensitive and drug-resistant *Mycobacterium tuberculosis*.

TBI-223 had significant efficacy against MRSA infections, including in bacteremia, nondiabetic and diabetic skin wound infections, and OIAI.

TBI-223 had efficacy comparable to that of linezolid in all of the mouse models of bacteremia, nondiabetic and diabetic skin wound models, and OIAI.

## References

Gordon O, et al. *Microbiol Spectr*. 2022 Oct 26;10(5):e0245121.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com